fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

EU approves Rinvoq in Crohn’s disease – AbbVie

Written by | 1 Jun 2023

AbbVie announced the European Commission (EC) approved Rinvoq (upadacitinib, 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) as the first oral Janus Kinase (JAK)… read more.

AbbVie provides update on Rinvoq for the treatment of rheumatoid arthritis in the U.S

Written by | 30 Jan 2022

AbbVie announced an update to the U.S. Prescribing Information and Medication Guide for Rinvoq (upadacitinib) for the treatment of adults with moderate to severe rheumatoid arthritis (RA). This… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.